New combination treatment enables targeting of non-responsive lung tumours
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
List view / Grid view
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
A human pancreatic cancer fibrotic barrier model illuminates how targeting the TGFβ/ROCK2/YAP signalling axis could enhance drug delivery.
Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases.
In this Q&A, Ichan Mount Siani researchers Dr Diego Chowell and Dr Robert Samstein share their new insights about the associations between human leukocyte antigen (HLA) class II loci and lung cancer risk.
A highly specific blood test can differentiate between patients with sarcoidosis and other respiratory conditions, like TB or lung cancer.
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
New findings about how RBM10 inhibits lung cancer growth offers potential for an anti-cancer drug and more personalised treatment.
New understanding of how lung cancer cells become more aggressive when nutrient deprived could lead to novel combination treatments.
Lactate producing bacteria is responsible for rewiring metabolic signalling pathways, causing resistance to radiation therapy.
US study uncovers the best way to treat recurrent or progressive brain metastases using an amino acid PET technique.
Researchers from China have formulated a robotics system that can access areas in the lung non-invasively before cancer diagnosis.
Spreading cancer can halt natural pathway that should recruit killer T cells directly to where it has metastasised, US scientists report.
US researchers found that the severity of muscle wasting from cancer is related to the type, size and location of the tumour, in mice.
Researchers have discovered a new cancer immunotherapy approach that shrinks solid tumours.
Researchers found that fibroblasts had varying effects on tumour cells based on both the type of non-small cell lung cancer and the drug used for treatment.